Point72 Asset Management, L.P. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 4:09 pm Sale | 2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Point72 Asset Management, L.P. | 496 0.000% | -1,471,275 (-99.97%) | Filing |
| 2024-01-02 4:15 pm Purchase | 2023-12-21 | 13G | Syros Pharmaceuticals, Inc. SYRS | Point72 Asset Management, L.P. | 1,471,771 5.700% | 1,471,771 (New Position) | Filing |